HCA (HCA) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks
Open on Zacks
HCA (HCA) Reports Q3 Earnings: What Key Metrics Have to Say

For the quarter ended September 2026, HCA Healthcare (HCA) reported revenue of $19.85 billion, up 3.6% over the same period last year. EPS came in at $7.22, compared to $6.96 in the year-ago quarter.

The reported revenue represents a surprise of +2.5% over the Zacks Consensus Estimate of $19.36 billion. With the consensus EPS estimate being $6.74, the EPS surprise was +7.12%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how HCA performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue per Equivalent Admission: $18,583.00 versus the five-analyst average estimate of $18,269.87. Equivalent Admissions: 1.07 billion compared to the 1.06 billion average estimate based on five analysts. Admissions: 592.18 million versus 587.13 million estimated by three analysts on average. Patient Days: 2,734.44 Days versus 2,687.52 Days estimated by two analysts on average. Average Length of Stay: 5 versus 5 estimated by two analysts on average. Number of hospitals: 189 compared to the 190 average estimate based on two analysts. Inpatient Revenue per Admission: $20,059.00 compared to the $20,762.76 average estimate based on two analysts. Equivalent Patient Days: 4.93 million versus 4.84 million estimated by two analysts on average. Licensed Beds at End of Period: 50,424 versus the two-analyst average estimate of 50,852. Number of freestanding outpatient surgery centers: 117 versus 118 estimated by two analysts on average.

View all Key Company Metrics for HCA here>>>

Shares of HCA have returned +7.6% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
HCA Healthcare, Inc. (HCA): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research